A financial summary of certain period activity related to our collaboration agreements is presented below1,2: | | | | | | | | | | | | | | Three-Month Periods Ended March 31, | | | Research and Development Expense | | | | | Upfront Fees | | Milestones | | Termination of Agreements | | Amortization of Prepaid R&D and Intangibles | | Equity Investments Made During Period | Acceleron | 2015 | $— | | $— | | $— | | $— | | $— | | 2014 | — | | — | | — | | — | | 15.0 | Epizyme | 2015 | — | | — | | — | | — | | — | | 2014 | — | | — | | — | | — | | 9.9 | FORMA | 2015 | 19.0 | | — | | — | | — | | — | | 2014 | 225.0 | | — | | — | | — | | — | MorphoSys | 2015 | — | | — | | 8.1 | | — | | — | | 2014 | — | | — | | — | | — | | — | NantBioScience(3) | 2015 | — | | — | | — | | — | | — | | 2014 | 50.0 | | — | | — | | — | | 90.0 | Other Collaboration Arrangements | 2015 | — | | — | | — | | 5.5 | | — | | 2014 | 34.0 | | — | | — | | 3.8 | | 20.9 |
A financial summary of the period-end balances related to our collaboration agreements is presented below: | | | | | | | | | | Balances as of: | | Intangible Asset Balance | | Equity Investment Balance | | Percentage of Outstanding Equity | Acceleron | March 31, 2015 | | $— | | $175.5 | | 14% | | December 31, 2014 | | — | | 179.7 | | 14% | Epizyme | March 31, 2015 | | — | | 69.0 | | 9% | | December 31, 2014 | | — | | 69.3 | | 11% | FORMA | March 31, 2015 | | 0.1 | | — | | N/A | | December 31, 2014 | | 0.1 | | — | | N/A | MorphoSys | March 31, 2015 | | — | | 50.3 | | 3% | | December 31, 2014 | | — | | 73.9 | | 3% | NantBioScience | March 31, 2015 | | — | | 90.0 | | 13% | | December 31, 2014 | | — | | 90.0 | | 14% | Other Collaboration Arrangements | March 31, 2015 | | 76.0 | | 633.2 | | N/A | | December 31, 2014 | | 67.7 | | 720.8 | | N/A |
| | 1 | Activity and balances are presented specifically for notable new collaborations and for those collaborations which we have described in detail in our 2014 Annual Report on Form 10-K if there has been new significant activity during the periods presented. Amounts related to collaborations that are not specifically described are presented in the aggregate as Other Collaboration Arrangements. |
| | 2 | In addition to the expenses noted in the tables above, we may also incur expenses for collaboration agreement related activities that are managed or funded by us. |
| | 3 | $25.0 million of expense related to the settlement of contingent matching contributions was also recognized at the inception of the collaboration agreement with NantBioScience during the three-month period ended March 31, 2014 and included in Selling, General and Administrative expense. |
|